The mesna, doxorubicin, ifosfamide, dacarbazine regimen produced a 47% response 
rate (including 10% complete responses) in 105 eligible adults with advanced 
sarcoma. The major dose-limiting toxicity was granulocytopenia. There was one 
toxic death from sepsis. Central nervous system and renal toxicity occurred 
infrequently, perhaps as a result of the continuous-infusion schedule. This 
regimen is being evaluated further in advanced disease, the adjuvant setting, 
and in combination with bone marrow colony-stimulating factors.